I think the future looks really bright for immunotherapeutic approaches for neurodegenerative diseases. We have the success of some of the monoclonal antibodies that have been approved. They’re first in class. They’re not perfect. They have side effects. For a-beta and Alzheimer’s disease there’s this risk of ARIA that comes associated with the monoclonal antibodies. ARIA meaning brain edema and micro hemorrhages which is a big hurdle to applying it clinically and for clinicians to use it...
I think the future looks really bright for immunotherapeutic approaches for neurodegenerative diseases. We have the success of some of the monoclonal antibodies that have been approved. They’re first in class. They’re not perfect. They have side effects. For a-beta and Alzheimer’s disease there’s this risk of ARIA that comes associated with the monoclonal antibodies. ARIA meaning brain edema and micro hemorrhages which is a big hurdle to applying it clinically and for clinicians to use it. But then there’s others following behind like our own PMN 310 where our monoclonal antibody only binds toxic oligomers not plaque not monomers so we should be able to at least that’s the concept to achieve efficacy by getting rid of the toxic oligomers without inducing ARIA because we don’t bind plaque. So there will be followers best in class after first in class and I think we’re there, so there’s there’s many approaches following behind targeting other facets of disease like neuroinflammation. None of these diseases are just one factor it’s multifactorial so you can approach it from different angles like neuroinflammation and then you could combine different medications together to get an even better effect. So I think we’re headed for better efficacy and better safety and I think it’s right around the corner.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
